Publicis Vital takes Paliperidon launch

Janssen-Cilag GmbH, a subsidiary of Johnson & Johnson, has handed the market launch of anti-psychotic drug Paliperidon to Publicis Vital PR.

The agency has already worked for the Neuss based pharmaceutical company on launches for Risperdal and Risperdal Consta.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in